Gout References

REFERENCES

Khanna D, Fitzgerald JD, Khanna PP, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-1446. http://www.ncbi.nlm.nih.gov/pubmed/?term=23024028. PMID: 23024028
Schlesinger N. Diagnosis of gout: clinical, laboratory and radiologic findings. Am J Manag Care. 2005 Nov;11(Suppl 15):S443-450. http://www.ncbi.nlm.nih.gov/pubmed/?term=Schlesinger++N%09%22Diagnosis++of++gout%3A++clinical%2C++laboraory++and+radiologic+finding%22. PMID: 16300458
Khanna D, Khanna PP, Fitzgerald JD, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1447-1461. http://www.ncbi.nlm.nih.gov/pubmed/?term=Khanna++D%2C+Khanna++PP%2C+Fitzgerald++JD%2C+et++al%09%222012+American+College+of+Rheumatology+guidelines+for+management+of+gout.+Part++2%3A+therapy+and+antiinflamatory++prophylaxis+of++acute+gouty++arthritis%22. PMID: 23024029
Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010 Mar;22(2):165-172. http://www.ncbi.nlm.nih.gov/pubmed/?term=Choi%2C+HK%09A+prescription+for+lifestyle+change+in+patients+with+hyperuricemia++and++gout. PMID: 20035225
Tausche A, Jansen T, Schroder H, et al. Gout - current diagnosis and treatment. Dtsch Arztebl Int. 2009 Aug;106:549-555. doi: 10.3238/arztebl.2009.0549. PMID: 19795010
Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of acute arthritis of primary gout. Arthritis Rheum. 1977 Apr;20(3):895-900. http://www.ncbi.nlm.nih.gov/pubmed/?term=856219. PMID: 856219
Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies including Therapeutics (ESCISIT). Ann Rheum Dis. 2006 Oct;65(10):1312-1324. PMID: 16707532
Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006 Oct;65(10):1301-1311. http://www.ncbi.nlm.nih.gov/pubmed/16707533. PMID: 16707533
Wortmann RL. Gout and hyperuricemia. In: Firestein GS, Budd RC, Harris ED Jr, et al. Kelley's Textbook of Rheumatology. 8th ed. Philadelphia, PA: Saunders, Elsevier; 2008.
Jordan J, Cameron S, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. MD Consult. http://www.mdconsult.com. 2007. Accessed 10 Jan 2012.
Becker M. Clinical manifestation and diagnosis of gout. UpToDate. http://www.uptodate.com. Accessed 20 Jan 2012.
National Institute for Health and Care Excellence (NICE). Pegloticase for treating severe chronic tophaceous gout. NICE. http://publications.nice.org.uk/pegloticase-for-treating-severe-debilitating-chronic-tophaceous-gout-ta291/about-this-guidance. Jun 2013.
Perez-Ruiz F, Dalbeth N, Urresola A, et al. Imaging of gout: findings and utility. Arthritis Research and Therapy. Medscape. http://www.medscape.com. 2009. Accessed 10 Jan 2012.
Malaysian Society of Rheumatology. Clinical practice guidelines: management of gout. Academy of Medicine of Malaysia. http://www.acadmed.org.my. Oct 2008. Accessed 10 Jan 2012.
Becker MA. Treatment of acute gout. UpToDate. https://www.uptodate.com/contents/treatment-of-acute-gout. Jun 2016. Accessed 26 Jul 2016.
Li-Yu J, Salido EO, Manahan S, et al; in behalf of the Philippine Rheumatology Association. Philippine clinical practice guideline for the management of gout. Philippine College of Physicians (PCP). http://www.pcp.org.ph/documents/CPGs/PRA/Gout%20CPG%20Manuscript%20_PJIM%20072808_.pdf. 2016. Accessed 26 Jul 2016.
Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015 Oct;67(10):2557-2568. http://onlinelibrary.wiley.com/doi/10.1002/art.39254/epdf. Accessed 26 Jul 2016. PMID: 26352873
Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2017 Jul;56(7):e1-e20. doi: 10.1093/rheumatology/kex156. Accessed 14 Aug 2018. PMID: 28549177
Paul BJ, James R. Gout: an Asia-Pacific update. Int J Rheum Dis. 2017 Apr;20(4):408-416. doi: 10.1111/1756-185X.13103. Accessed 14 Aug 2018. PMID: 28585370
Qaseem A, Harris RP, Forciea MA. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017 Jan;166(1):58-68. doi: 10.7326/M16-0570. Accessed 14 Aug 2018. PMID: 27802508
Chohan S. Gout and hyperuricemia. In: Kellerman R, Bope E. Conn's Current Therapy 2018; 2018. http://dx.doi.org/10.1016/B978-0-323-52769-9.00061-1. Accessed 03 Apr 2018:281-284.
Edwards NL. Crystal deposition diseases. In: Goldman L, Schafer A. Goldman-Cecil Medicine. 25th ed; 2016. http://dx.doi.org/10.1016/B978-1-4557-5017-7.00273-7. Accessed 03 Apr 2018:1811-1816.e2.
Bernstein S. New draft gout guideline released. The Rheumatologist. https://www.the-rheumatologist.org. 20 Nov 2019. Accessed 28 Feb 2020.
Editorial. Hitting the target in gout. The Lancet Rheumatology. 2020 Jan;2(1). https://doi.org/10.1016/S2665-9913(19)30131-6.
Li Q, Li X, Wang J, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019 Aug;9(8):e026677. doi: 10.1136/bmjopen-2018-026677. Accessed 28 Feb 2020. PMID: 31446403
FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020 Jun;72(6):744-760. doi: 10.1002/acr.24180. Accessed 22 May 2020. PMID: 32391934
Gaffo AL. Treatment of gout flares. UpToDate. https://www.uptodate.com. 03 Feb 2022.
Golenbiewski J, Keenan RT. Moving the needle: improving the care of the gout patient. Rheumatol Ther. 2019 Jun;6(2):179-193. doi: 10.1007/s40744-019-0147-5. PMID: 30826988
Pascart T, Latourte A, Flipo RM, et al. 2020 Recommendations from the French Society of Rheumatology for the management of gout: urate-lowering therapy. Joint Bone Spine. 2020 Oct;87(5):395-404. doi: 10.1016/j.jbspin.2020.05.002. Accessed 10 Mar 2022. PMID: 32422338
Perez-Ruiz F. Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout. UpToDate. https://www.uptodate.com. 16 Dec 2020.
Ministry of Health Malaysia, Malaysian Society of Rheumatology, Academy of Medicine Malaysia. Clinical practice guidelines. Management of gout (second edition). Academy of Medicine of Malaysia. http://www.acadmed.org.my. Nov 2021. Accessed 18 Oct 2022.
Low QJ, Lim TH, Hon SA, et al. Management of gout in the primary care setting. Malays Fam Physician. 2022 Mar 28;17(1):2-9. doi: 10.51866/rv1165. PMID: 35440955
Yip RML, Cheung TT, So H, et al. The Hong Kong Society of Rheumatology consensus recommendations for the management of gout. Clin Rheumatol. 2023 Apr 4. doi: 10.1007/s10067-023-06578-9. PMID: 37014501
Chohan S. Gout and hyperuricemia. In: Kellerman R, Bope E. Conn’s Current Therapy 2018; 2018. 281-284. :281-284.

AZD7442 (tixagevimab–cilgavimab) prevents COVID-19 in high-risk populations

Dr. Leong Hoe Nam, Dr. Behram Ali Khan, Dr. See Hui Ti, Dr. Yoon Kam Hon, 12 Oct 2022

Though most COVID-19 safe management measures have been lifted in Singapore, the pandemic continues to adversely impact the lives of immunocompromised patients at high risk of severe infection.

“It has been an absolute misery for these patients and their families,” said Dr Leong Hoe Nam, Infectious Disease Specialist at Mount Elizabeth Novena Hospital, Singapore. “The virus is an unseen enemy that may strike unexpectedly. The strike may kill, or if not, maim the individual. Patients isolate themselves for fear of getting infected while their family members fear bringing the illness back home.”

Immunocompromised patients are those with suppressed immunity resulting from health conditions, including solid organ and haematological cancers, end-stage kidney and liver disease, organ or bone marrow transplants, and immune-mediated inflammatory diseases such as rheumatoid arthritis, or those on active treatment with immunosuppressive medications. [Expert Rev Vaccines 2022;1-17; BMJ 2021;374:n2098]

Updates in the Management of Osteoporotic Fracture Risk

Dr. Chionh Siok Bee, Dr. Charles A Inderjeeth, 29 Nov 2018

Osteoporosis is a bone condition characterized by reduced bone mass and microarchitectural deterioration of bone tissue, consequently increasing bone fragility and fracture susceptibility.¹ Despite being a major cause of death and disability, osteoporosis is significantly underdiagnosed and undertreated in Asia.² At a recent symposium supported by the Osteoporosis Society (Singapore) and organized by Amgen, local expert Dr Chionh Siok Bee presented an overview of the fracture landscape in Singapore, while internationally renowned guest speaker Dr Charles A Inderjeeth discussed the importance of identifying and managing osteoporosis fracture risk, with a focus on the role of antiresorptive agent denosumab.

Managing comorbidities in rheumatoid arthritis in the new decade

Prof. Peter Taylor, Prof. Christopher Edwards, Dr. Lian Tsui Yee, 03 Nov 2021

Nearly half of all rheumatoid arthritis (RA) patients suffer comorbidity, which has a negative impact on quality of life and mortality. At a recent scientific symposium, Professor Peter Taylor from the University of Oxford in Oxford, UK emphasized the importance of monitoring, preventing, and treating comorbidities in RA while Professor Christopher Edwards from the University Hospital Southampton in Southampton, UK focused on the impact of mental health in RA. The symposium was organized by Fresenius Kabi and held under the auspices of the Singapore Society of Rheumatology. Dr Lian Tsui Yee from Tan Tock Seng Hospital, Singapore chaired the event.